<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03884660</url>
  </required_header>
  <id_info>
    <org_study_id>CR1393</org_study_id>
    <nct_id>NCT03884660</nct_id>
  </id_info>
  <brief_title>remedē System Therapy Study</brief_title>
  <official_title>remedē System Therapy Study (rēST Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Respicardia, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Respicardia, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this non-randomized post market registry is to collect clinical data on the
      safety and effectiveness of the remedē System in a real-world setting.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center, prospective, open label, non-randomized study to collect safety and
      effectiveness data in subjects with central sleep apnea implanted with the remedē System. At
      least 500 subjects will be successfully implanted at approximately 50 sites in the United
      States and Europe.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 18, 2019</start_date>
  <completion_date type="Anticipated">April 15, 2027</completion_date>
  <primary_completion_date type="Anticipated">April 15, 2027</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate safety of the remedē System at implant and protocol required follow up: Percentage of patients with related serious adverse events.</measure>
    <time_frame>5 years</time_frame>
    <description>Percentage of patients with related serious adverse events.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Apnea Hypopnea Index (AHI) from baseline</measure>
    <time_frame>1, 3, and 5 years</time_frame>
    <description>Evaluate changes in AHI as measured with in-lab polysomnogram (PSG) (1 year) and home sleep apnea test (HSAT) (3 and 5 years)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Epworth Sleepiness Scale (ESS) from baseline</measure>
    <time_frame>Baseline, 6 months, and 1, 2, 3, 4 and 5 years</time_frame>
    <description>Evaluate changes in daytime sleepiness using the ESS. The ESS total score, an assessment of daytime sleepiness, is the sum of the 8 item-scores.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Patient Reported Outcome Measurement Information System (PROMIS)-29 from baseline</measure>
    <time_frame>Baseline, 6 months, and 1, 2, 3, 4 and 5 years</time_frame>
    <description>Evaluate impact on the PROMIS-29 questionnaire.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate overall quality of life using Patient Global Assessment (PGA)</measure>
    <time_frame>6 months and 1 year</time_frame>
    <description>Percentage of subjects indicating marked or moderate improvement in PGA.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in Kansas City Cardiomyopathy Questionnaire KCCQ at 6 months</measure>
    <time_frame>Baseline, 6 months, and 1 and 2 years</time_frame>
    <description>Evaluate impact on the KCCQ in the heart failure subgroup.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in ejection fraction in the subgroup of subjects with heart failure</measure>
    <time_frame>1 year</time_frame>
    <description>Evaluate reverse remodeling in the subgroup of subjects with heart failure.</description>
  </primary_outcome>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Central Sleep Apnea</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>remede System</intervention_name>
    <description>Patients undergoing a remede System implant attempt. Study devices will be used per approved indications for use for each geography.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects who are determined to be candidates, independent of this research study, to
        receive a de novo commercial implant of the remedē System are eligible for inclusion in
        this trial, subject to the entry criteria.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Subjects who are determined to be candidates to receive a de novo commercial implant of the
        remedē System are eligible for inclusion in this trial, subject to the entry criteria.

        Entry Criteria:

          1. Moderate to severe central sleep apnea (AHI ≥ 15 events per hour) based on a sleep
             study scored by a local sleep laboratory. It is recommended that a patient have a PSG
             within 12 months of the expected implant date documenting moderate to severe CSA.

          2. Age 18 years or older

          3. Signed Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved
             informed consent

          4. In the opinion of the investigator, subject is willing and able to comply with the
             protocol.

          5. Not currently enrolled in another investigational study or registry that would
             directly interfere with the current study, except if the subject is participating in a
             mandatory government registry, or a purely observational registry with no associated
             treatments. Each instance should be brought to the attention of the sponsor to
             determine eligibility.

          6. In the opinion of the Investigator, life expectancy exceeds one year.

          7. The subject is not pregnant or planning to become pregnant.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jennifer Miller, MS</last_name>
    <phone>952-641-4445</phone>
    <email>jmiller@respicardia.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Heather Clary</last_name>
    <phone>952-641-4441</phone>
    <email>hclary@respicardia.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Grant Stalker</last_name>
      <email>grant.stalker@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Liviu Klein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado Health</name>
      <address>
        <city>Fort Collins</city>
        <state>Colorado</state>
        <zip>80528</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Turner</last_name>
      <email>sara.turner@uchealth.org</email>
    </contact>
    <investigator>
      <last_name>Mark Neagle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Metro Health- University of Michigan Health</name>
      <address>
        <city>Wyoming</city>
        <state>Michigan</state>
        <zip>49519</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cindy Karl</last_name>
      <email>cindy.karl@metro.org</email>
    </contact>
    <investigator>
      <last_name>Matthew Sevensma, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Metro Health</name>
      <address>
        <city>Wyoming</city>
        <state>Michigan</state>
        <zip>49519</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cindy Karl, RN</last_name>
      <phone>616-252-4971</phone>
      <email>cindy.karl@metrogr.org</email>
    </contact>
    <investigator>
      <last_name>Matthew Sevensma, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Valley Hospital</name>
      <address>
        <city>Paramus</city>
        <state>New Jersey</state>
        <zip>07652</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Polites, RN</last_name>
      <phone>201-447-8453</phone>
      <email>spolite@valleyhealth.com</email>
    </contact>
    <investigator>
      <last_name>Suneet Mittal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwell Health</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11040</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ramona Ramdeo</last_name>
    </contact>
    <investigator>
      <last_name>Harly Greenberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York Presbyterian Hospital-Weill Cornell Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Glum</last_name>
    </contact>
    <investigator>
      <last_name>James Ip, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Forsyth Medical Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leslie Tucker</last_name>
      <email>ltucker@novanthealth.org</email>
    </contact>
    <investigator>
      <last_name>Michael Drucker</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Ohio State Wexner Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Brougher</last_name>
      <email>sarah.brougher@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Ralph Augostini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Penn State Health Milton S. Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paula Trump</last_name>
      <email>ptrump1@pennstatehealth.psu.edu</email>
    </contact>
    <investigator>
      <last_name>John Boehmer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>March 19, 2019</study_first_submitted>
  <study_first_submitted_qc>March 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 21, 2019</study_first_posted>
  <last_update_submitted>April 30, 2020</last_update_submitted>
  <last_update_submitted_qc>April 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Apnea, Central</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

